colleen craig md
play

COLLEEN CRAIG, MD Clinical Development of Avexitide Senior Medical Advisor for Hyperinsulinemic Hypoglycemia Eiger BioPharmaceuticals Instructor Stanford University School of Medicine 1 AVEXITIDE (EXENDIN 9-39) First-in-class GLP-1 Receptor

0 downloads 6 Views 1,48 MB Size Report
  1. COLLEEN CRAIG, MD Clinical Development of Avexitide Senior Medical Advisor for Hyperinsulinemic Hypoglycemia Eiger BioPharmaceuticals Instructor Stanford University School of Medicine 1

  2. AVEXITIDE (EXENDIN 9-39) First-in-class GLP-1 Receptor Antagonist with Inverse Agonist Properties N-terminus 31-amino-acid fragment of exendin-4, a 39 amino-acid • naturally occurring peptide GLP-1 Antagonist and Investigational product in development by Eiger BioPharmaceuticals Inverse Agonist • for the treatment of hyperinsulinemic hypoglycemia (HI) 39 patients with HI have received avexitide by continuous IV infusion • under 3 proof-of-concept studies conducted at CHOP Eiger has developed a stable, sterile solution formulation for • subcutaneous injection (SC avexitide injection). 63 adults have received avexitide SC injection to date • - 40 healthy volunteers - 23 patients with post-bariatric hypoglycemia, of which 18 patients self- injected avexitide once or twice daily for 28 days 2 CHOP = Children’s Hospital of Philadelphia

  3. AVEXITIDE TARGETS THE GLP-1 RECEPTOR Inhibition of GLP-1 Receptor Signaling Reduces Fasting and Postprandial Hyperinsulinemia Preclinical studies in a mouse model of K ATP HI 1 and in pancreatic islets from patients with HI 2 have demonstrated critical role of GLP-1r in K ATP HI and elucidated Avexitide’s mechanism of action: Avexitide binds to the GLP-1r • Competes with endogenous GLP-1 at the receptor • (antagonist) Prevents basal GLP-1r signaling (inverse agonist) • Reduces cAMP-mediated insulin release • Reduces fasting and postprandial hyperinsulinemia • Represents a targeted therapeutic approach • 3 1. De Leon et al. J Biol Chem. 2008;283(38):25786 – 25793; 2. Calabria et al. Diabetes. 2012;61(10):2585 – 2591

  4. PROOF OF CONCEPT DEMONSTRATED IN MULTIPLE CLINICAL TRIALS Intravenous and Subcutaneous Administration in Patients with Hyperinsulinemic Hypoglycemia 4

  5. CONCLUSIONS • Avexitide is a first-in-class GLP-1 receptor antagonist with inverse agonist properties • The GLP-1 receptor plays an important role in the mechanisms mediating K ATP HI • Three Proof of Concept studies of Avexitide in K ATP HI at CHOP (IV infusion; n=39) - Demonstrated reduction in fasting and postprandial hyperinsulinemic hypoglycemia Eiger has developed a stable, solution formulation of avexitide for subcutaneous injection (SC • avexitide injection) and has evaluated this formulation in 63 adults • SC avexitide injection has been well-tolerated with no treatment-related SAEs or withdrawals • Future investigations in patients with K ATP HI may employ SC avexitide injection 5

  6. COMMITTED TO RARE DISEASES

Recommend Documents


2 thanks to colleen and jessica for being on today as
2. Thanks to Colleen and Jessica for

1. Thank you to Colleen and the USL for inviting me 2. Thanks to Colleen and

end of life options the key issues
End-of-Life Options: The Key Issues

End-of-Life Options: The Key Issues Professor Colleen Cartwright Director ,

fundamentals and management students
Fundamentals and Management Students

Fundamentals and Management Students Photos during Simulation Experience

ailsa ai sa craig craig area area
Ailsa Ai sa Craig Craig & Area

MAY 13, 2014 Page 1 of 17 11.A.1 - CW 161 Ailsa Craig Main Street P.O. Box

effective presentations a must
Effective PresentationsA Must Craig J.

Angewandte . Editorial DOI: 10.1002/anie.201209795 Effective PresentationsA

city of craig economic
City of Craig economic development

City of Craig economic development efforts Craig/Moffat Economic Development

food access programs farm sales farmers market viability
Food Access Programs, Farm Sales,

Food Access Programs, Farm Sales, & Farmers Market Viability Colleen

welcome to the rda wheatbelt nsrf information session
Welcome to the RDA Wheatbelt NSRF

Welcome to the RDA Wheatbelt NSRF Information Session Guest presenter -

craig interpolation in displayable logics
Craig interpolation in displayable

Craig interpolation in displayable logics James Brotherston 1 and Rajeev Gor e

bridging clouds
Bridging Clouds with Keystone to

Bridging Clouds with Keystone to Keystone Federation Vishakha Agarwal

opioid replacement therapy
OPIOID REPLACEMENT THERAPY Dr.

OPIOID REPLACEMENT THERAPY Dr. Niloofer Baria Disclosures Nil Overview

control id 152096 presentation type symposium secondary
CONTROL ID: 152096 PRESENTATION TYPE:

See discussions, stats, and author profiles for this publication at:

managing the effect cts of op opio ioid ids s on your pool
Managing the Effect cts of Op Opio

5/16/18 Managing the Effect cts of Op Opio ioid ids s on Your Pool

dementia
Dementia (or whatever you call it)

WEST VIRGINIA INTEGRATED BEHAVIORAL HEALTH CONFERENCE Dementia (or whatever

background
Background Julie A. Moran, D.O.

9/30/2014 Practical Evaluation of the Adult with Intellectual/Developmental

art therapy transforming aging through crea5vity in
Art Therapy: Transforming Aging

Art Therapy: Transforming Aging through Crea5vity in Community

serina therapeutics
Serina Therapeutics Randall Moreadith,

Serina Therapeutics Randall Moreadith, MD, PhD President and CEO SER-214

mat capable recovery residences
MAT-Capable Recovery Residences

MAT-Capable Recovery Residences Challenges and Opportunities for Addressing

effects of a ppar delta gamma agonist t3d 959 on
Effects of a PPAR Delta/Gamma Agonist,

1 Effects of a PPAR Delta/Gamma Agonist, T3D-959, on Metabolic and Cognitive

a retrospective evaluation of glycemic effects in
A Retrospective Evaluation of Glycemic

A Retrospective Evaluation of Glycemic Effects in Veterans With Type 2

importance of calcium assay parameters in drug discovery
Importance of calcium assay parameters

Actelion Pharmaceutical Allschwill Hamamatsu 10th FDSS User Meeting June 2014

asd sd work orking grou oup mole olecular tar arget
ASD SD Work orking Grou oup Mole

ASD SD Work orking Grou oup Mole olecular Tar arget Literature Review